Phase II Trial of cTACE Plus Sintilimab for Treatment of Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
Latest Information Update: 24 May 2024
At a glance
- Drugs Sintilimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 May 2024 Status changed from recruiting to completed.
- 24 Oct 2023 Results (n=20) ssessing the efficacy and safety of sintilimab plus cTACE for HCC with stage BCLC B (or stage CNLC IIa-IIb) beyond up-to-seven criteria presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Status changed from not yet recruiting to recruiting.